Ovid Therapeutics (OVID) Stock Forecast & Price Target

Ovid Therapeutics is viewed favorably because OV329 targets a clinically validated epilepsy mechanism, GABA-AT inhibition, while being engineered to avoid vigabatrin’s irreversible eye toxicity and deliver meaningful efficacy at mg-scale doses rather than gram-scale dosing. The lead asset has shown encouraging Phase 1 tolerability across 68 volunteers, no ophthalmologic findings across five modalities, and cortical inhibition exceeding vigabatrin’s PD signal at 400–600x lower dose, supporting a potential first-in-class profile in drug-resistant focal onset seizures, TSC, and infantile spasms. The bullish case is further strengthened by a cash runway into 2029, multiple near-term catalysts including photosensitivity, PPR, and Ph2a readouts, and additional upside from OV4071 and the KCC2 franchise in a strategic area with multi-billion potential.

Ovid Therapeutics is facing a negative outlook because its pipeline remains highly speculative, with only 10% probability of approval assigned to OV888 and 30% to OV329, while key risks include clinical failure, regulatory delays, partnership setbacks, and long-term dilution. Despite a differentiated epilepsy focus, the commercial opportunity is constrained by modest precedent sales of about $220M in 2017 for Sabril, a drug whose uptake was limited by vigabatrin-specific ocular toxicity, and the company still must prove that its candidates can deliver safer, durable efficacy in hard-to-treat populations. Financially, Ovid reported a 2Q26 net loss of $0.08 per share, held $169.8M in cash and securities as of June 30, 2026, and is expected to fund operations into 2029, but the valuation still depends heavily on uncertain clinical execution.